Prevalence of human papillomavirus in 5,072 consecutive cervical SurePath samples evaluated with the Roche cobas HPV real-time PCR assay.

New commercially available Human Papillomavirus (HPV) assays need to be evaluated in a variety of cervical screening settings. Cobas HPV Test (cobas) is a real-time PCR-based assay allowing for separate detection of HPV genotypes 16 and 18 and a bulk of 12 other high-risk genotypes. The aim of the p...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sarah Preisler, Matejka Rebolj, Anette Untermann, Ditte Møller Ejegod, Elsebeth Lynge, Carsten Rygaard, Jesper Bonde
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2013
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/899d765884c34c3fbade742a1c1512b6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:899d765884c34c3fbade742a1c1512b6
record_format	dspace
spelling	oai:doaj.org-article:899d765884c34c3fbade742a1c1512b62021-11-18T07:52:14ZPrevalence of human papillomavirus in 5,072 consecutive cervical SurePath samples evaluated with the Roche cobas HPV real-time PCR assay.1932-620310.1371/journal.pone.0059765https://doaj.org/article/899d765884c34c3fbade742a1c1512b62013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23533648/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203New commercially available Human Papillomavirus (HPV) assays need to be evaluated in a variety of cervical screening settings. Cobas HPV Test (cobas) is a real-time PCR-based assay allowing for separate detection of HPV genotypes 16 and 18 and a bulk of 12 other high-risk genotypes. The aim of the present study, Horizon, was to assess the prevalence of high-risk HPV infections in an area with a high background risk of cervical cancer, where women aged 23-65 years are targeted for cervical screening. We collected 6,258 consecutive cervical samples from the largest cervical screening laboratory in Denmark serving the whole of Copenhagen. All samples were stored in SurePath media. In total, 5,072 samples were tested with cobas, Hybrid Capture 2 High Risk HPV DNA test (HC2) and liquid-based cytology. Of these, 27% tested positive on cobas. This proportion decreased by age, being 43% in women aged 23-29 years and 10% in women aged 60-65 years. HC2 assay was positive in 20% of samples, and cytology was abnormal (≥ atypical squamous cells of undetermined significance) for 7% samples. When only samples without recent abnormalities were taken into account, 24% tested positive on cobas, 19% on HC2, and 5% had abnormal cytology. The proportion of positive cobas samples was higher than in the ATHENA trial. The age-standardized cobas positivity vs. cytology abnormality was 3.9 in our study and 1.7 in ATHENA. If in Copenhagen the presently used cytology would be replaced by cobas in women above age 30 years, an extra 11% of women would based on historical data be expected to have a positive cobas test without an underlying cervical intraepithelial lesion grade 3 or worse. Countries with a high prevalence of HPV infections should therefore proceed to primary HPV-based cervical screening with caution.Sarah PreislerMatejka ReboljAnette UntermannDitte Møller EjegodElsebeth LyngeCarsten RygaardJesper BondePublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 3, p e59765 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Sarah Preisler Matejka Rebolj Anette Untermann Ditte Møller Ejegod Elsebeth Lynge Carsten Rygaard Jesper Bonde Prevalence of human papillomavirus in 5,072 consecutive cervical SurePath samples evaluated with the Roche cobas HPV real-time PCR assay.
description	New commercially available Human Papillomavirus (HPV) assays need to be evaluated in a variety of cervical screening settings. Cobas HPV Test (cobas) is a real-time PCR-based assay allowing for separate detection of HPV genotypes 16 and 18 and a bulk of 12 other high-risk genotypes. The aim of the present study, Horizon, was to assess the prevalence of high-risk HPV infections in an area with a high background risk of cervical cancer, where women aged 23-65 years are targeted for cervical screening. We collected 6,258 consecutive cervical samples from the largest cervical screening laboratory in Denmark serving the whole of Copenhagen. All samples were stored in SurePath media. In total, 5,072 samples were tested with cobas, Hybrid Capture 2 High Risk HPV DNA test (HC2) and liquid-based cytology. Of these, 27% tested positive on cobas. This proportion decreased by age, being 43% in women aged 23-29 years and 10% in women aged 60-65 years. HC2 assay was positive in 20% of samples, and cytology was abnormal (≥ atypical squamous cells of undetermined significance) for 7% samples. When only samples without recent abnormalities were taken into account, 24% tested positive on cobas, 19% on HC2, and 5% had abnormal cytology. The proportion of positive cobas samples was higher than in the ATHENA trial. The age-standardized cobas positivity vs. cytology abnormality was 3.9 in our study and 1.7 in ATHENA. If in Copenhagen the presently used cytology would be replaced by cobas in women above age 30 years, an extra 11% of women would based on historical data be expected to have a positive cobas test without an underlying cervical intraepithelial lesion grade 3 or worse. Countries with a high prevalence of HPV infections should therefore proceed to primary HPV-based cervical screening with caution.
format	article
author	Sarah Preisler Matejka Rebolj Anette Untermann Ditte Møller Ejegod Elsebeth Lynge Carsten Rygaard Jesper Bonde
author_facet	Sarah Preisler Matejka Rebolj Anette Untermann Ditte Møller Ejegod Elsebeth Lynge Carsten Rygaard Jesper Bonde
author_sort	Sarah Preisler
title	Prevalence of human papillomavirus in 5,072 consecutive cervical SurePath samples evaluated with the Roche cobas HPV real-time PCR assay.
title_short	Prevalence of human papillomavirus in 5,072 consecutive cervical SurePath samples evaluated with the Roche cobas HPV real-time PCR assay.
title_full	Prevalence of human papillomavirus in 5,072 consecutive cervical SurePath samples evaluated with the Roche cobas HPV real-time PCR assay.
title_fullStr	Prevalence of human papillomavirus in 5,072 consecutive cervical SurePath samples evaluated with the Roche cobas HPV real-time PCR assay.
title_full_unstemmed	Prevalence of human papillomavirus in 5,072 consecutive cervical SurePath samples evaluated with the Roche cobas HPV real-time PCR assay.
title_sort	prevalence of human papillomavirus in 5,072 consecutive cervical surepath samples evaluated with the roche cobas hpv real-time pcr assay.
publisher	Public Library of Science (PLoS)
publishDate	2013
url	https://doaj.org/article/899d765884c34c3fbade742a1c1512b6
work_keys_str_mv	AT sarahpreisler prevalenceofhumanpapillomavirusin5072consecutivecervicalsurepathsamplesevaluatedwiththerochecobashpvrealtimepcrassay AT matejkarebolj prevalenceofhumanpapillomavirusin5072consecutivecervicalsurepathsamplesevaluatedwiththerochecobashpvrealtimepcrassay AT anetteuntermann prevalenceofhumanpapillomavirusin5072consecutivecervicalsurepathsamplesevaluatedwiththerochecobashpvrealtimepcrassay AT dittemøllerejegod prevalenceofhumanpapillomavirusin5072consecutivecervicalsurepathsamplesevaluatedwiththerochecobashpvrealtimepcrassay AT elsebethlynge prevalenceofhumanpapillomavirusin5072consecutivecervicalsurepathsamplesevaluatedwiththerochecobashpvrealtimepcrassay AT carstenrygaard prevalenceofhumanpapillomavirusin5072consecutivecervicalsurepathsamplesevaluatedwiththerochecobashpvrealtimepcrassay AT jesperbonde prevalenceofhumanpapillomavirusin5072consecutivecervicalsurepathsamplesevaluatedwiththerochecobashpvrealtimepcrassay
_version_	1718422866592006144

Prevalence of human papillomavirus in 5,072 consecutive cervical SurePath samples evaluated with the Roche cobas HPV real-time PCR assay.

Ejemplares similares